PT  - JOURNAL ARTICLE
AU  - TARHINI, AHMAD A.
AU  - ZAHOOR, HARIS
AU  - MCLAUGHLIN, BRIAN
AU  - GOODING, WILLIAM E
AU  - SCHMITZ, JOHN C.
AU  - SIEGFRIED, JILL M.
AU  - SOCINSKI, MARK A.
AU  - ARGIRIS, ATHANASSIOS
TI  - Phase I Trial of Carboplatin and Etoposide in Combination with Panobinostat in Patients with Lung Cancer
DP  - 2013 Oct 01
TA  - Anticancer Research
PG  - 4475--4481
VI  - 33
IP  - 10
4099  - http://ar.iiarjournals.org/content/33/10/4475.short
4100  - http://ar.iiarjournals.org/content/33/10/4475.full
SO  - Anticancer Res2013 Oct 01; 33
AB  - A phase I trial consisting of panobinostat (a HDAC inhibitor), carboplatin and etoposide was condacted in patients with lung cancer. Patients and Methods: Patients received carboplatin AUC5 on day 1 and etoposide 100 mg/m2 on days 1, 2 and 3, every 21 days. Concurrent oral panobinostat was given 3 times weekly on a 2-weeks-on and 1-week-off schedule during the 4-6 cycles of chemotherapy and then continued as maintenance therapy. Results: Six evaluable patients were treated at the first dose level of panobinostat (10 mg). Dose-limiting toxicity occurred in two patients (33%) during the first cycle. One patient developed grade 4 thrombocytopenia and another grade 4 febrile neutropenia. Therefore, the study was suspended based on the pre-specified study design. No recommended phase II starting dose was established. Conclusion: The addition of panobinostat to carboplatin and etoposide was not tolerable at the lowest dose level tested in this trial. Further research and development into this combination is not recommended.